Ad
related to: Sinopharm (company)Explore Genmab's Unique Platforms for Creating Enhanced Antibodies. See How Genmab Works to Push Boundaries While Also Driving Sustainability.
- Careers
Join our Mission to Improve
the Lives of Patients.
- Pipeline
Review our Pipeline and
See How We're Changing Treatment.
- Sign Up
Sign Up for Updates, News
and Much More.
- About Us
Discover the Unique Approach
That Makes Genmab Different.
- Approved Medicines
See the Approved Treatments
Using Our Antibody Science.
- Antibody Science
Explore Our Unique Platforms
For Creating Antibody Treatments.
- Careers
Search results
China National Pharmaceutical Group Corporation (CNPGC), commonly referred to as Sinopharm, is a Chinese state-owned enterprise.
The bio-pharm sector of China National Pharmaceutical Group Co Ltd (Sinopharm) consists of more than 20 production enterprises, with China National Biotec Group Company Limited at its core.
People also ask
Who owns Sinopharm Group?
Who is Sinopharm medicine?
Is Sinopharm Group listed on the Hong Kong stock exchange?
What does Sinopharm do in the retail sector?
Sinopharm Group Co., Ltd. is a Chinese pharmaceutical company. The parent company of Sinopharm Group was Sinopharm Industrial Investment, a 51–49 joint venture of state-owned enterprise China National Pharmaceutical Group and civilian-run enterprise Fosun Pharmaceutical.
Sinopharm is the largest vaccine producer globally, supplying over 85 percent of vaccines for the national immunization schedule. It also has the strongest blood product manufacturing capacity in China, with an annual plasma collection volume of over 2,000 tons.
Sinopharm is a globally leading company in the healthcare sector in terms of scale, performance and comprehensive strength. With a primary focus on life & health, the company owns a complete industrial chain covering R&D, manufacturing, logistics and distribution, retail chains, healthcare, engineering technology, exhibitions and events ...
Sinopharm Group Co. Ltd. (the “Company”, “Sinopharm” or “Sinopharm Group”, together with its subsidiaries referred to as the “Group”), which was established in January 2003 and listed on The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) (stock code: 01099.
Dec 30, 2020 · A Vaccine Made From Coronaviruses. BBIBP-CorV works by teaching the immune system to make antibodies against the SARS-CoV-2 coronavirus. The antibodies attach to viral proteins, such as the...
Ad
related to: Sinopharm (company)
